KPRX vs. TTPH, JAGX, NBRV, KRON, DARE, LEXX, CLNN, AADI, IMRX, and EYEN
Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Tetraphase Pharmaceuticals (TTPH), Jaguar Health (JAGX), Nabriva Therapeutics (NBRV), Kronos Bio (KRON), Daré Bioscience (DARE), Lexaria Bioscience (LEXX), Clene (CLNN), Aadi Bioscience (AADI), Immuneering (IMRX), and Eyenovia (EYEN). These companies are all part of the "medical" sector.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
42.3% of Tetraphase Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 5.7% of Tetraphase Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Tetraphase Pharmaceuticals'average media sentiment score.
Kiora Pharmaceuticals has a consensus target price of $2.00, indicating a potential upside of 337.06%. Given Tetraphase Pharmaceuticals' higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500.
Kiora Pharmaceuticals has a net margin of 0.00% compared to Kiora Pharmaceuticals' net margin of -798.18%. Tetraphase Pharmaceuticals' return on equity of 17.90% beat Kiora Pharmaceuticals' return on equity.
Kiora Pharmaceuticals has lower revenue, but higher earnings than Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals received 371 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 68.42% of users gave Kiora Pharmaceuticals an outperform vote while only 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote.
Summary
Kiora Pharmaceuticals beats Tetraphase Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get Kiora Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiora Pharmaceuticals Competitors List
Related Companies and Tools
